REFERENCES

4. IMS Market Prognosis, Apr 2011.
7. World Preview 2016 Evaluate Pharma, Jun 2011
World Review, 2005, Pharma Strategy Group, 2005
9. IMS Health, National Sales Perspectives, Sep 2010.
26. US Trade Stats Express, International Trade Administration, Govt. of USA.


39. Nagaraj Naidu’s speech at India-China Pharma Conference in Shanghai - Jun 2011


43. S. Kannan. Testing times for India’s pharma industry, Asia Times, 2005.

47. IHS Global Insight, Increasing Demand for Indian Drugs Prompts Calls for Permanent U.S. FDA Presence in India, 2007.
54. Interview with Sue Capie. CEO. PharmaVantage. 2009.

63. WO. Foye, Thomas L. Lemke, et al., Foye's principles of medicinal chemistry, Lippincott Williams & Wilkins. 335


75. LE. Panattoni. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms, J Health Econ.; 30(1), 2011:126-45.


78. ParagraphFour.com.


